Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07402876 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
A Phase 3 study of Primary Vitreoretinal Lymphoma, sponsored by Aldeyra Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07402876: Recruiting Phase 3 study of Primary Vitreoretinal Lymphoma, sponsored by Aldeyra Therapeutics.
NCT07402876 is a Phase 3 study of Primary Vitreoretinal Lymphoma that is actively recruiting participants, run by Aldeyra Therapeutics. The registered enrollment target is 20 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07402876, a Phase 3 study of Primary Vitreoretinal Lymphoma, is actively recruiting participants, sponsored by Aldeyra Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma
Conditions Studied
Interventions
- DRUG ICM ADX-2191 injection
- DRUG Monthly ADX-2191 injection
Study Locations (1)
Florida
- Bascom Palmer Eye Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What NCT07402876 shows while recruiting
NCT07402876 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Primary Vitreoretinal Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which ICM ADX-2191 injection is the first listed.
NCT07402876 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07402876 about?
NCT07402876 is a clinical study titled "A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma". A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma
What is the current status of trial NCT07402876?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2026-02. Estimated completion is 2026-12.
What conditions does trial NCT07402876 study?
This clinical trial studies the following conditions: Primary Vitreoretinal Lymphoma.
What interventions are being tested in trial NCT07402876?
The interventions under investigation include: ICM ADX-2191 injection (DRUG), Monthly ADX-2191 injection (DRUG).
Who is sponsoring clinical trial NCT07402876?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07402876 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07402876's enrollment target sits among peer trials
20 1957th of 2000 higher than 32 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia